Form 4: Eloxx CEO Sumit Aggarwal Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Eloxx Pharmaceuticals CEO Sumit Aggarwal has been granted 328,833 stock options following the satisfaction of performance-based vesting conditions.
Summary
- CEO Sumit Aggarwal was granted 328,833 stock options with an exercise price of $1.65.
- The grant was originally issued on September 19, 2025, but remained subject to performance-based vesting conditions.
- Performance conditions were officially satisfied on June 10, 2026.
- The options will begin vesting on July 31, 2026, with 1/36th of the total amount vesting monthly over 35 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation that does not signal a change in company fundamentals.
Positives
- Alignment of executive compensation with long-term performance goals.
- Successful satisfaction of performance-based vesting criteria by the CEO.
Negatives
- Potential for future shareholder dilution upon the exercise of these options.
Risks
- Continued service requirement for the full vesting of the option grant.
- Market price volatility affecting the value of the options relative to the $1.65 exercise price.
Future Outlook
The options will vest over a 36-month period starting July 31, 2026, contingent upon the CEO's continued service to the company.
Management Comments
- The filing confirms the satisfaction of performance-based vesting conditions for the CEO's equity compensation.
Industry Context
StockSavvy.ai notes that performance-based equity grants are standard practice in the biotechnology sector to incentivize leadership during critical clinical development phases.
Comparison to Industry Standards
- The use of performance-based vesting is consistent with governance best practices for small-cap pharmaceutical companies.
- The 36-month vesting schedule is standard for executive retention in the life sciences industry.
Stakeholder Impact
- Shareholders may experience minor dilution if options are exercised in the future.
Next Steps
- Commencement of monthly vesting schedule on July 31, 2026.
Key Dates
| Date | Description |
|---|---|
| 09/19/2025 | Original grant date of the stock options. |
| 06/10/2026 | Date performance conditions were satisfied and transaction reported. |
| 07/31/2026 | Initial vesting date for the option grant. |
| 09/19/2035 | Expiration date of the stock options. |
Keywords
Eloxx Pharmaceuticals, ELOX, Sumit Aggarwal, Stock Options, Executive Compensation, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.